Evaluating the Role of Ultrasound in Prostate Cancer trial - phase 1: Early experience of micro-ultrasound in the United Kingdom
- PMID: 39493923
- PMCID: PMC11528729
- DOI: 10.1177/1742271X231226302
Evaluating the Role of Ultrasound in Prostate Cancer trial - phase 1: Early experience of micro-ultrasound in the United Kingdom
Abstract
Purpose: The purpose of this study was to evaluate if the use of micro-ultrasound can detect clinically significant prostate pathology when compared to histology obtained during a transperineal prostate biopsy.
Methods: Patients suspected of having prostate cancer, who had a pre-biopsy magnetic resonance imaging and could tolerate a transrectal examination, were prospectively recruited. All patients had a micro-ultrasound scan prior to their biopsy. The findings of magnetic resonance imaging, micro-ultrasound and histology were risk stratified in accordance with local pathways. Comparison of assigned risk scores was made using histology as the reference standard.
Results: Data from 101 patients were evaluated. Histology showed that clinically significant prostate cancer was detected in 48.5% (n = 49/101) of patients. Moderate inter-rater agreement was found in both magnetic resonance imaging and micro-ultrasound with К of 0.31 in both modalities. High-risk findings were identified in 81% (n = 82/101) patients at magnetic resonance imaging and in 66% (n = 67/101) patients at micro-ultrasound. Sensitivity and specificity of magnetic resonance imaging were found to be 87% and 34.6% and for micro-ultrasound 73.3% and 53.8%, respectively.
Conclusion: A limitation of this study was that the biopsy was not performed with micro-ultrasound which may have resulted in unidentified cancers and lowered the apparent accuracy of the technique. However, we conclude that while micro-ultrasound was diagnostic, magnetic resonance imaging demonstrated higher sensitivity in our local population and remains the pre-biopsy imaging modality of choice. However, the higher specificity of micro-ultrasound identified does indicate that it may be of value when magnetic resonance imaging is contraindicated. The role of micro-ultrasound, within an active surveillance pathway for prostate cancer, warrants further investigation.
Keywords: Sonographer; active surveillance; diagnosis; micro-ultrasound; prostate biopsy.
© The Author(s) 2024.
Conflict of interest statement
The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.
Similar articles
-
MRI software and cognitive fusion biopsies in people with suspected prostate cancer: a systematic review, network meta-analysis and cost-effectiveness analysis.Health Technol Assess. 2024 Oct;28(61):1-310. doi: 10.3310/PLFG4210. Health Technol Assess. 2024. PMID: 39367754 Free PMC article.
-
Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation.Clin Orthop Relat Res. 2025 Jan 1;483(1):39-48. doi: 10.1097/CORR.0000000000003161. Epub 2024 Jun 21. Clin Orthop Relat Res. 2025. PMID: 38905450
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
-
Magnetic resonance perfusion for differentiating low-grade from high-grade gliomas at first presentation.Cochrane Database Syst Rev. 2018 Jan 22;1(1):CD011551. doi: 10.1002/14651858.CD011551.pub2. Cochrane Database Syst Rev. 2018. PMID: 29357120 Free PMC article.
-
Thoracic imaging tests for the diagnosis of COVID-19.Cochrane Database Syst Rev. 2022 May 16;5(5):CD013639. doi: 10.1002/14651858.CD013639.pub5. Cochrane Database Syst Rev. 2022. PMID: 35575286 Free PMC article.
References
-
- Vasarainen H, Salman J, Salminen H, et al.. Predictive role of free prostate-specific antigen in a prospective active surveillance program (PRIAS). World J Urol 2015; 33: 1735–1740. - PubMed
-
- Bruinsma SM, Zhang L, Roobol MJ, et al.. The Movember Foundation’s GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date. BJU Int 2018; 121: 737–744. - PubMed
-
- Prostate Cancer UK, https://prostatecanceruk.org/ (2020, accessed 16 October 2023).
-
- Movember Foundation. Prostate cancer, https://uk.movember.com/about/prostate-cancer (2020, accessed 23 September 2022).
LinkOut - more resources
Full Text Sources